<DOC>
	<DOCNO>NCT02449681</DOCNO>
	<brief_summary>This phase 2 study design evaluate safety activity TH-4000 ( Tarloxotinib ) , hypoxia-activated prodrug participant recurrent metastatic squamous cell carcinoma head neck skin .</brief_summary>
	<brief_title>Study Treatment Patients With Recurrent Metastatic SCCHN SCCS</brief_title>
	<detailed_description>An open label , parallel-group , multi-center Phase 2 study pharmacokinetics , safety , tolerability efficacy TH-4000 ( Tarloxotinib ) assess participant recurrent metastatic squamous cell carcinoma head neck skin . Hypoxia PET scan obtain select center analyze potential predictor tumor response .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Confirmed squamous cell carcinoma head neck ( oropharynx , oral cavity , hypopharynx , larynx ) skin For patient oropharyngeal cancer , p16 status know determine Measurable disease accord Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) Acceptable laboratory result indicate protocol Acceptable cardiac function indicate protocol Received prior EGFR TKI therapy recurrent metastatic SCC ( e.g. , oral EGFR TKIs erlotinib , gefitinib , afatinib ) Family history long QTc syndrome Receiving medication prolongs QT interval , risk cause Torsades de Pointes ( TdP ) , unless ECG meet inclusion criterion stable dose medication Family history long QTc syndrome Symptomatic central nervous system ( CNS ) lesion , CNS lesion require therapy Radiation therapy within 2 week prior first dose study medication Major surgery within 4 week minor surgery within 2 week prior first dose study medication Concurrent active malignancy require systemic treatment Any serious uncontrolled medical disorder psychological condition may interfere study conduct include limited : clinically significant active infection Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>head neck</keyword>
	<keyword>skin</keyword>
	<keyword>TH-4000</keyword>
	<keyword>Hypoxia</keyword>
	<keyword>Tarloxotinib</keyword>
</DOC>